ArticleEndocrine2021
Race and sex differences in the initiation of diabetes drugs by privately insured US adults.
Abstract readLetter
In one paragraph
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.Current cardiology reports · 2026Pooled it
- Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012-2021.Journal of general internal medicine · 2026Article
- Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk.Journal of the American Heart Association · 2025Article
- Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk.Nature cardiovascular research · 2024Article
- Enrollment in High-Deductible Health Plans and Incident Diabetes Complications.JAMA network open · 2024Article
- Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis.Journal of managed care & specialty pharmacy · 2023Article
- Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment.BMC pulmonary medicine · 2023Article
- Advances in the management of type 2 diabetes in adults.BMJ medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Rozalina G McCoyDepartment of Medicine, Division of Community Internal Medicine, Mayo Clinic, Rochester, MN, USA. mccoy.rozalina@mayo.edu.ORCID 0000-0002-2289-3183
Holly K Van HoutenMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Shannon M DunlayMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Xiaoxi YaoMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Timothy DempseyDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Peter A NoseworthyMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Lindsey R SangaralinghamMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Andrew H LimperMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Nilay D ShahMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Funding
Yale-Mayo FDA Center for Excellence in Regulatory Science and InnovationU01FD005938 · FDA · YALE UNIVERSITY · PI Joseph Solomon Ross · 2016 to 2026
$25.4MPA-20-072: Accelerating the Use of Evidence-based Innovation in Healthcare SystemsU19HS024075 · AHRQ · DARTMOUTH COLLEGE · PI MEARA, ELLEN R. · 2015 to 2021
$19.8MTranslational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4MPneumocystis: Macrophage & Epithelial ActivationR01HL062150 · NHLBI · MAYO CLINIC ROCHESTER · PI ANDREW H LIMPER · 1998 to 2026
$9.2MCARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7MAdvanced Heart Failure: Epidemiology and OutcomesR01HL144529 · NHLBI · MAYO CLINIC ROCHESTER · PI DUNLAY, SHANNON MARIE · 2019 to 2023
$3.6MShared decision making for stroke prevention in atrial fibrillation (SDM4Afib)R01HL131535 · NHLBI · MAYO CLINIC ROCHESTER · PI MONTORI, VICTOR MANUEL · 2016 to 2020
$3.2MInfluence of genetic variation on QT prolongation over the lifecourse and as a cardiotoxic drug responseR01HL143070 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NEWTON-CHEH, CHRISTOPHER HOLMES · 2018 to 2021
$3.0MOptimizing stroke prevention for older adults with atrial fibrillation: Towards rigorous evaluation and judicious application of a new deviceR01AG062436 · NIA · MAYO CLINIC ROCHESTER · PI NOSEWORTHY, PETER A, YAO, XIAOXI · 2020 to 2024
$2.5MGastrointestinal Safety of Antithrombotic Drug RegimensR01HS025402 · AHRQ · MAYO CLINIC ARIZONA · PI ABRAHAM, NEENA S · 2017 to 2020
$1.6MMedical reversals: De-implementing ineffective and unsafe treatmentsR01HS025164 · AHRQ · UNIVERSITY OF MINNESOTA · PI KARACA-MANDIC, PINAR · 2017 to 2020
$1.4MPredicting the Risk of Severe Hypoglycemic and Hyperglycemic Events in Adults with DiabetesK23DK114497 · NIDDK · MAYO CLINIC ROCHESTER · PI MCCOY, ROZALINA GRUBINA · 2017 to 2021
$846kAHRQ HHS R01 HS025164AHRQ HHS R01 HS025402AHRQ HHS R03 HS025517AHRQ HHS U19 HS024075FDA HHS U01 FD005938NHLBI NIH HHS R01 HL062150NHLBI NIH HHS R01 HL131535NHLBI NIH HHS R01 HL143070NHLBI NIH HHS R01 HL144529NHLBI NIH HHS R03 HL135225NHLBI NIH HHS R21 HL140205NHLBI NIH HHS R56 HL130496NHLBI NIH HHS T32 HL007111NIA NIH HHS R01 AG062436NIDDK NIH HHS K23 DK114497NIDDK NIH HHS P30 DK111024
Abstract
PubMed holds no abstract for this paper.
Indexed as
Diabetes MellitusPharmaceutical PreparationsAdultFemaleHumansInsurance, HealthMaleSex CharacteristicsUnited StatesPharmaceutical Preparations
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.